CAS NO: | 2162134-62-3 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
生物活性 | Garadacimab (CSL312) is a first-in-class, fully humanIgG4monoclonal antibody targetingactivated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research[1]. |
体外研究 (In Vitro) | Garadacimab (CSL312) displays high affinity to activated βFXIIa with a KDof 140 pM and shows potency in an activated partial thromboplastin time (aPTT) assay with human plasma. Garadacimab shows high selectivity over a panel of relevant human serine proteases (FVIIa, FIXa, FXa, FXIa, kallikrein, tissue plasminogen activator, activated protein C, and urokinase plasminogen activator)[2]. |
体内研究 (In Vivo) | In male and female cynomolgus monkeys, Garadacimab (0.5, 1, and 3 mg/kg i.v. and 6 and 20 mg/kg s.c. over 8 weeks) plasma concentrations increased in a dose-dependent manner[1]. |
CAS 号 | 2162134-62-3 |
中文名称 | 加达西单抗 |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |